Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside

Significant progress has been achieved over the last decades in understanding the biology and mechanisms of tumor progression in urothelial carcinoma (UC). Although the therapeutic landscape has dramatically changed in recent years with the introduction of immune checkpoint inhibitors, advanced UC i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ungaro, Antonio, Tucci, Marcello, Audisio, Alessandro, Di Prima, Lavinia, Pisano, Chiara, Turco, Fabio, Delcuratolo, Marco Donatello, Di Maio, Massimo, Scagliotti, Giorgio Vittorio, Buttigliero, Consuelo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909578/
https://www.ncbi.nlm.nih.gov/pubmed/35269424
http://dx.doi.org/10.3390/cells11050803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909578/
https://www.ncbi.nlm.nih.gov/pubmed/35269424
http://dx.doi.org/10.3390/cells11050803

Ejemplares similares